Verified employee & interview reviews

Syneos Health Reviews

Morrisville, North Carolina

4.0/ 5

1 review

Syneos Health is a prominent global biopharmaceutical solutions organization that operates as a fully integrated Contract Research Organization (CRO) and Contract Commercial Organization (CCO). Formed in 2018 through a $7.4 billion merger between INC Research (founded in 1998) and InVentiv Health, the company was intentionally designed to bridge the gap between clinical development and commercialization. This unique operational approach, known as the Biopharmaceutical Acceleration Model (BAM), synchronizes clinical trial behaviors with real-world commercial insights to shorten the distance from laboratory discovery to patient delivery. Headquartered in Morrisville, North Carolina, the company employs approximately 28,000 professionals and maintains an extensive operational footprint spanning more than 110 countries across five continents. The core operations of Syneos Health are divided into two primary business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions vertical provides comprehensive end-to-end biopharmaceutical outsourcing services, specializing in Phase I-IV clinical trial management, data integrity, regulatory navigation, and global trial execution. The company possesses specialized therapeutic expertise in areas such as oncology, central nervous system (CNS) disorders, neuroscience, rare diseases, and immunology. Notably, the firm has contributed to the development or commercialization of 96% of novel oncology drugs approved by the FDA in recent five-year periods. The Commercial Solutions vertical focuses on market access, physician engagement, medical affairs, healthcare communications, and product launch strategies, enabling pharmaceutical and biotechnology firms to successfully market health treatments. To maintain its competitive positioning, Syneos Health utilizes advanced technology frameworks, including proprietary data-mining and enrollment-prediction tools. In 2023, the organization entered a multi-year strategic collaboration with Microsoft Research to develop platforms leveraging machine learning for the optimization of clinical trials. Culturally, Syneos Health prioritizes diversity, equity, and inclusion, supported by a formal DE&I Council and employee-led Employee Resource Groups (ERGs) designed to integrate diverse sub-groups within the workforce. Financially, Syneos Health transitioned from a publicly traded entity on the Nasdaq exchange to a private corporation in September 2023. The transition followed a $7.1 billion private equity acquisition (including debt) by an investment consortium consisting of Elliott Investment Management, Patient Square Capital, and Veritas Capital. This acquisition allowed the organization to pursue private restructuring and focus on long-term strategic investments in artificial intelligence and clinical operations. The executive leadership team is headed by Chief Executive Officer Costa Panagos, who was appointed to the role in October 2024. The firm serves a wide customer continuum, providing specialized consulting, standalone services, and integrated end-to-end outsourcing solutions to small, mid-sized, and multinational pharmaceutical, biotechnology, and medical device corporations worldwide.